But the Anglo-Swedish group, which is headquartered in Cambridge, also revealed some oncology drug success on Monday with the announcement that its Enhertu treatment showed “a statistically significant and clinically meaningful improvement in progression-free survival” for non-small cell lung cancer patients.
